本報告已在2011年07月19日停止出版。
預測全球直接驅動設備市場從 2004- 2009 將以 10.6％ 的比率擴大。歐洲、中東、非洲地區是線性馬達元件的最大市場，亞洲則是線性馬達系統的最大市場，未來亞太地區各國的直接驅動設備市場將會持續擴大。
擅長半導體、電子產品、工業用電子通訊產品市調分析的英國專業公司 IMS Research（總公司：威靈伯魯市），調查分析了南北美洲直接驅動設備市場後，出版了一本綜合報告書 "The America Market for Direct Drives - 2005 Edition"。
報告書調查市場線性馬達元件、線性馬達系統、扭力馬達三大產品領域市場動向、未來預測、2004 年市佔率、市場企業概要等等，內容綱要摘記如下：
摘要
第1章 前言、範圍與方法論
- 前言、調查目的
- 範圍
- 產品定義
- 市場價值測定點
- 各地區詳述
- 產業部門
- 各產品規模
- 各地區
- 銷售網路
- 各軸數（僅線性馬達系統）
- 報告書內容
- 調查方法
- 經濟性預測
- GDP 的相關性、產業界生產與生產狀況
- GDP 前 50 大國家
- 主要經濟發展預測方法
- 平均銷售價格預測與台數分析
第2章 全球市場
- 前言
- 市場擴大分析
- 市場動向
- 直接驅動器市場
- 各產品種類市場
- 各產品尺寸市場
- 各產業領域市場
- 各地區市場
- 各銷售網路市場
- 各軸數市場
- 各精確度市場
- 直接驅動器競爭環境
第3章 南北美洲市場
- 前言
- 地區擴大分析
- 直接驅動器市場
- 地區市場
- 各產品種類市場
- 各產品尺寸市場
- 各產業領域市場
- 各地區市場
- 各銷售網路市場
- 各軸數市場
- 各精確度市場
- 競爭環境
附錄 1 企業名錄
Abstract
Some of the top level results from the study include:
- The world market for direct drives is forecast to grow by 10.6% over the
forecast period 2004-2009.
- EMEA is the largest region for linear motor components; conversely the
largest market for linear motor systems is Asia Pacific.
- The Asia Pacific region is forecast to experience the highest levels of
growth for direct drives.
- Customers are moving from purchasing linear motor components to purchasing
linear motor systems.
- Major industry sectors for direct drives include: semiconductor machinery,
machine tools, electronics and electronics assembly, and flat panel display
machinery.
This is one of the many findings from the latest IMS Research study on the
worldwide market for direct drives. The report provides market forecasts and
analysis of the World and the Americas markets for three different products:
linear motor components, linear motor systems, and torque motors. For each of
the above segmentations the report is further sub-divided by: product type
(for linear motors only), product size, industry sector, geographic region,
sales channel, and number of axis (for linear motor systems only). A detailed
analysis of these results, which are provided both in terms of revenues and
unit shipments, is also included.
An analysis of the competitive environment is also provided, including market
shares for 2004, as well as a matrix of companies active in the market.
This study is ideal for anyone looking for a detailed quantitative analysis of
the worldwide and the Americas direct drives market. This includes
manufacturers looking to enter the direct drives market, or a particular
product range in this market, as well as companies looking to break into new
regional markets, as well as investment bankers and VC's.
Table of Contents
Chapter 1: Executive Summary 1�E
Chapter 2: Biopharmaceuticals are Recombinant Products that Replicate
Functions or Antibodies that are Inhibitory 2�E
- Reengineering Medicines 2�E
- Humanized Chimeric Antibodies 2�EEngineered Fusion Proteins𨫎ith and without
Fc 2�E
- PEGylation 2�E
- Glycosylation 2�E0
- Growth Hormones and Enzymes 2�E1
- Human Growth Factors and Enzymes Approved by FDA in 2004 and 2005 2�E2
- Categorization of Growth Factors and Hormones 2�E3
- Therapeutic Antibodies 2�E6
- Economic Considerations of the Commercial Manufacture of Antibodies 2�E7
- Commercialization of Antibody Production 2�E9
- Purification Considerations 2�E1
- Monoclonal Antibody Successes in the Clinic 2�E2
- Antibodies Entering the Clinic 2�E6
- FDA Approval of 18 Therapeutic Antibodies 2�E6
- Therapeutic Approved Antibodies𤋺utside the US 2�E7
- Cytokines嫎 Potential $12�E15 Billion 2005 Market 2�E8
- Survival Factors (SCF, CNTF, BDGF) 2�E9
- FDA Approved Cytokines IL-2 and interferon-alfa 2b and GM-CSF 2�E0
- Interleukin-2 2�E1
- Granulocyte-Monocyte Colony Stimulating Factor 2�E2
- Interleukin-12 2�E2
- Vaccines 2�E2
- Pasteur and the Discovery of Active Immunization 2�E2
- Pediatric Vaccines 2�E5
- Disease Eradication 2�E5
- Cancer Vaccines 2�E7
- Vaccines and Bioterrorism 2�E8
- A Comparison of Pharmaceutical Expression Systems 2�E0
- The Emerging Industry of Plant-Made Pharmaceuticals and Biopharming 2�E3
- Farming Biopharma Drugs䊼rops as Bioreactors 2�E6
- Plant Cell Cultures Currently in Use for Commercial Recombinant
Biopharmaceuticals 2�E9
- Transgenic Animal Factories Cows, Chickens, and Rabbits 2�E2
- Notable Companies Using Transgenics 2�E4
- Process Development 2�E5
Chapter 3: Proteins/Antibodies as Drugs 3�E
- Basic Protein Biochemistry 3�E
- The Amino Acids 3�E
- Chaperone Proteins 3�E
- Protein Structure 3�E
- The Ribosome 3�E1
- Post-Translational Modification 3�E2
- Proteolytic Cleavage 3�E3
- The Coagulation Cascade 3�E4
- Protein Cross Linking 3�E5
- Glycosylation 3�E6
- Biochemistry of Glycosylation 3�E6
- Glycosylated Precursor in the Endoplasmic Reticulum and Golgi Apparatus 3�E8
- Lysosomal Targeting of Enzymes 3�E2
- Clinical Significances of Glycoproteins 3�E2
- Vitamin C-Dependent Modifications 3�E3
- Vitamin K-Dependent Modifications 3�E4
- Acetylation 3�E4
- Phosphorylation 3�E5
- Kinases 3�E6
- Sulfation 3�E6
- Prenylation, Farnesylation, and Geranylgeranylation 3�E8
- Protein Degradation: The Ubiquitin Pathway 3�E0
- Ubiquitin Function 3�E1
- The Ubiquitin-Proteasome Pathway 3�E1
- What are the degradation signals? 3�E1
- How Does Ubiquitination Lead to Protein Degradation? 3�E2
- The Proteasome 3�E3
- The 20S Proteasome Chamber 3�E3
- The Function of the Proteasome 3�E4
- S Proteasome 3�E4
- Proteasomes and the Immune Response 3�E4
- Comparing the Proteasome and Chaperon 3�E5
- Bioreactors for Synthesis of Proteins 3�E5
- Prokaryotic Expression Systems𦝁he Earliest Bioreactor 3�E6
- What is the Future for Bacterial Fermentation? 3�E8
- Single Cell Eukaryotic Based Protein Synthesis 3�E8
- Current Commercial Biopharmaceuticals Made in Yeast and Fungal Expression
Systems 3�E0
- Glycosylation of Therapeutic Proteins 3�E1
- Baculovirus and Insect Cell-Based Protein Synthesis 3�E2
- Mammalian Cell-Based Protein Expression 3�E5
- Hybridomas and at the Production of Monoclonal Antibodies 3�E5
- To Suppress the Immune System 3�E5
- To Kill or Inhibit Malignant Cells 3�E5
- To Block Angiogenesis 3�E6
- Protein Expression in Mammalian Cells 3�E6
- Mammalian Transfection Protocols 3�E8
- Electroporation 3�E9
- Lipofection 3�E9
- Microinjection 3�E9
- Viral Expression Systems 3�E9
- Transient and Stable Transfection𦳀ammalian CHO cells 3�E0
- The Basic Antibody Response 3�E1
- Protein G Based Isolation of Monoclonal Antibody 3�E5
- Uses for Monoclonal Antibodies in Pathology 3�E5
- Transgenic Mice and Phage Display Libraries for Antibody Production 3�E6
- Problems with Monoclonal Therapy 3�E8
- The Science of Transgenes, using Plants and Animals as Drug Factories 3�E1
- How to Make Transgenic Plants 3�E1
- Potential Uses of the Transgenic Plants 3�E2
- Ethical and Political Concerns with Genetically Modified Plants 3�E3
- Transgenic Animals 3�E4
- Nuclear Transfer and Animal Cloning 3�E6
- Nuclear Transfer Technology 3�E6
- Therapeutic Cloning 3�E8
Chapter 4: Quality Control and Post-translational Modifications of
Recombinant Drugs 4�E
- Biopharmaceutical Formulation: Potential Post-Translational Alterations 4�E
- Biotherapeutic Proteins versus Small Molecule Drugs 4�E
- Drug Development Factors for Recombinant Biologicals 4�E
- Critical Factors in Protein Analysis 4�E
- Biologic Stability 4�E0
- Process Development of Recombinant Biologicals 4�E2
- Recombinant Therapeutic Systems 4�E4
- Solubilization of Expressed Recombinants 4�E7
- Glycosylation and Microheterogeneity Affecting Recombinant Drugs 4�E8
- Erythropoietin 4�E0
- Follicular Stimulating Hormone 4�E1
- A Plant's N-glycans Contains �E1,3)-fucose and �E1,2)-xylose 4�E3
- Protein Immunogenicity𡐓eoepitopes 4�E4
- Prenylation and Myristoylation 4�E6
- Vaccine Development 4�E7
- Farensyl Transferase Inhibitors in Cancer 4�E8
- Myristoylated Recombinant Proteins 4�E8
- Phosphorylation of Biopharmaceuticals 4�E9
- Sulfation and Disulfide Bond Formation 4�E1
- Disulfide Bonds and Recombinant Protein Activity/Stability 4�E1
- Thiolation and Sulfation of Therapeutic Proteins 4�E3
- Metabolic Transformations of Biopharmaceuticals 4�E5
- Acetylation and Acylation 4�E6
- Myristyl Acylation 4�E6
- Ubiquitinylation and Proteolytic Processing 4�E7
- Proteolytic Processing of Biopharmaceuticals 4�E9
- Degradomics 4�E0
- Oxidation of Biopharmaceuticals 4�E1
- Deamidation 4�E3
- Glycation of Therapeutic Proteins 4�E6
- Glycomics and Proteomics 4�E7
- Changing Glycosylation in Protein Expression Systems 4�E9
- Glycan-like Formulation Strategies for Protein Pharmaceuticals 4�E0
Chapter 5: Protection of Biopharmaceutical Products 5�E
- Recent Problems with Counterfeited Drugs𡐓ational Association of Boards of
Pharmacy Potential List of Counterfeit Medicines 5�E
- Anti-Counterfeiting Measures for Biopharmaceutical Brand Protection 5�E
- Financial Loss 5�E
- Brand Damage 5�E
- Organized Crime 5�E
- Terrorism 5�E
- Covert, Overt, and Forensic Solutions 5�E
- Nonprinted Security Features 5�E
Chapter 6: Products of the Leading Biopharmaceutical Companies 6�E
- Amgen Inc. 6�E
- Biogen Idec, Inc. 6�E
- Genentech, Inc. 6�E
- Serono, Inc. 6�E
- Eli Lilly and Company 6�E0
- Roche 6�E2
- Biogeneric娋iopharmaceutical Generics 6�E3
- The Hatch Waxman Act 6�E4
- US FDA Regulations 6�E4
- Invalidation of Amgen Patent for EPO in UK 6�E6
- Conclusions�E005 Sales Patterns 6�E9
- Overview 6�E1
TABLE OF EXHIBITS
- Exhibit 2.1 Biopharmaceuticals Approved and in the Market Through 2003 2�E
- Exhibit 2.2 Recent Chimeric Approved Antibodies To Date 2�E
- Exhibit 2.3 Humanized Antibodies in Clinical Trials in 2005 2�E
- Exhibit 2.4 FDA Approved Growth Hormones and Enzymes in 2004 and 2005 2�E2
- Exhibit 2.5 Summary of Growth Factors in R&D Stages 2�E3
- Exhibit 2.6 Flow Chart of Fundamental Steps in a Culture/bioreactor
Product 2�E1
- Exhibit 2.7 US and Europe Approved Therapeutic Antibodies Until 2005 2�E3
- Exhibit 2.8 2004 and 2005 FDA-approved Antibodies 2�E5
- Exhibit 2.9 Number of Therapeutic Monoclonal Antibodies Entering the
Clinic from 1984 to 2004 2�E6
- Exhibit 2.10 Bacterial/Viral Infections Targets for Vaccines 2�E7
- Exhibit 2.11 Types of Cancer Vaccines in Development 2�E8
- Exhibit 2.12 Companies Involved in Bioterror Vaccine Production 2�E0
- Exhibit 2.13 Advantages and Disadvantages of Different Expression Systems
2�E2
- Exhibit 2.14 Plant-derived Pharmaceuticals Close to Commercialization 2�E4
- Exhibit 2.15 Biotech Companies Specializing in Plant Made Pharmaceuticals
2�E8
- Exhibit 2.16 Expression Hosts and Yields of Recombinant Proteins in
Production 2�E0
- Exhibit 2.17 From a Transgenic Plants to a Commercial Product 2�E2
- Exhibit 2.18 Companies Involved in the Manufacture of Biopharmaceuticals
2�E5
- Exhibit 3.1 An Amino Acid 3�E
- Exhibit 3.2 The Peptide Bond in a Protein 3�E
- Exhibit 3.3 Amino Acids are Stereoisomers 3�E
- Exhibit 3.4 The 20 Naturally Occurring Amino Acids 3�E
- Exhibit 3.5 Hsp60 Chaperone Protein Crystal Structure 3�E
- Exhibit 3.6 Four Levels of Protein Structure 3�E
- Exhibit 3.7 Secondary Structure 3�E
- Exhibit 3.8 The Central Dogma 3�E0
- Exhibit 3.9 Transfer RNA 3�E0
- Exhibit 3.10 The Genetic Code 3�E1
- Exhibit 3.11 Protein Synthesis on the Ribosome 3�E2
- Exhibit 3.12 Common Post-Translational Modifications of Proteins 3�E3
- Exhibit 3.13 Cleavage Sites of Common Proteases 3�E4
- Exhibit 3.14 The Coagulation Cascade 3�E5
- Exhibit 3.15 The Amino Acid Cysteine Creates Disulfide Linkages 3�E6
- Exhibit 3.16 The Ring Structure of Monosaccharides 3�E7
- Exhibit 3.17 Common Monosaccharides and Disaccharides 3�E7
- Exhibit 3.18 The Glycosidic Bond 3�E8
- Exhibit 3.19 O Linked Carbohydrates 3�E0
- Exhibit 3.20 N Linked Carbohydrates 3�E1
- Exhibit 3.21 Dolichol Structure 3�E2
- Exhibit 3.22 Enzyme Defects in Degradation of Asn-GlcNAc Type
Glycoproteins 3�E3
- Exhibit 3.23 Structure of a Gla Residue 3�E4
- Exhibit 3.24 The Universal PAPS Reaction 3�E7
- Exhibit 3.25 Protein Prenylation 3�E9
- Exhibit 3.26 The Proteasome 3�E3
- Exhibit 3.27 Bioreactors for Protein Production 3�E6
- Exhibit 3.28 Advantages of an Expression System Using Protozoa 3�E9
- Exhibit 3.29 Yeasts S. Serevisiae and P. Pastoris Therapeutic Protein
Production 3�E2
- Exhibit 3.30 Baculovirus Expression System 3�E4
- Exhibit 3.31 Mammalian Transfection and Expression Protocol 3�E7
- Exhibit 3.32 Mammalian Expression Vector 3�E8
- Exhibit 3.33 Basic Techniques for Creating Hybridomas 3�E2
- Exhibit 3.34 Monoclonal Antibodies used in Pathology 3�E5
- Exhibit 3.35 Panning of Phage Libraries 3�E7
- Exhibit 3.36 Basic Antibody Structure 3�E8
- Exhibit 3.37 Cancer Clinical Trails using Monoclonal Antibodies till June,
2005 3�E0
- Exhibit 3.38 Current Genetically Modified Plant Studies 3�E2
- Exhibit 3.39 Microinjection for Creating Transgenic Animals 3�E4
- Exhibit 3.40 Microinjection Process 3�E5
- Exhibit 3.41 Breeding Protocol to Produce Homozygote Transgenic Animals 3�E5
- Exhibit 3.42 Drugs Currently Synthesized in Transgenic Animals 3�E6
- Exhibit 3.43 Cloning of Livestock 3�E7
- Exhibit 3.44 Therapeutic Cloning Protocol 3�E9
- Exhibit 4.1 FDA's Division of Therapeutic Proteins (DTP) Product Diversity
4�E
- Exhibit 4.2 Recombinant Protein Analysis Solutions 4�E
- Exhibit 4.3 Successful Isolation of a Recombinant Antitumor Immunoreagent
4�E0
- Exhibit 4.4 Shelf Life of Recombinant Protein Drugs 4�E1
- Exhibit 4.5 Stability-Indicating Test Methods for Recombinant Proteins 4�E1
- Exhibit 4.6 Solubilization Strategies for Expressed Recombinants 4�E8
- Exhibit 4.7 Microheterogeneity of FSH 4�E2
- Exhibit 4.8 Ubiquitinylation of Therapeutic Protein 4�E8
- Exhibit 4.9 Protein Oxidation Reactions 4�E2
- Exhibit 4.10 Protein Deamidation 4�E3
- Exhibit 5.1 Counterfeited Nutropin Vials 5�E
- Exhibit 5.2 NABP's list of Susceptible Products 5�E
- Exhibit 5.3 Anticounterfeiting Security Measures 5�E
- Exhibit 6.1 Amgen's Lead Biopharmaceuticals 6�E
- Exhibit 6.2 Biogen's Lead Biopharmaceuticals 6�E
- Exhibit 6.3 Genentech's Lead Biopharmaceuticals 6�E
- Exhibit 6.4 Serono's Lead Biopharmaceuticals 6�E
- Exhibit 6.5 Lilly's Lead Biopharmaceuticals 6�E1
- Exhibit 6.6 Top Biopharmaceuticals and Their Patent Positions in 2000 6�E6
- Exhibit 6.7 Disease Targets for Biopharmaceuticals 6�E1
